Department of Radiology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong Street, Taipei, 112, Taiwan.
Eur Radiol. 2021 Oct;31(10):7464-7475. doi: 10.1007/s00330-021-07843-8. Epub 2021 Mar 25.
To evaluate whether parenchyma-to-lipiodol ratio (PLR) and lesion-to-lipiodol ratio (LLR) on C-arm cone-beam computed tomography (CBCT) can predict 1-year tumor response in patients with hepatocellular carcinoma (HCC) treated with conventional transcatheter arterial chemoembolization (cTACE).
This retrospective analysis included 221 HCC target lesions within up-to-seven criteria in 80 patients who underwent cTACE with arterial-phase CBCT and unenhanced CBCT after cTACE from 2015 to 2018. PLR and LLR of every tumor slice were obtained through mean density division of liver parenchyma and tumor enhancement with intratumoral lipiodol deposition. The cutoff values (COVs) of maximal PLR and LLR of every tumor were analyzed using Youden's index. The reliability of COV, correlations between the related parameters, and 1-year progression were assessed through interobserver agreement and multivariate analysis. COV validity was verified using the chi-square test and Cramer's V coefficient (V) in the validation cohort.
Standard COVs of PLR and LLR were 0.149 and 1.4872, respectively. Interobserver agreement of COV for PLR and LLR was near perfect (kappa > 0.9). Multivariate analysis suggested that COV of PLR is an independent predictor (odds ratio = 1.23532×10, p = 4.37×10). COV of PLR showed strong consistency, correlation with 1-year progression in prediction model (V = 0.829-0.776; p < 0.0001), and presented as an effective predictor in the validation cohort (V = 0.766; p < 0.0001).
The COV of PLR (0.149) assessed through immediate post-embolization CBCT is an objective, effective, and approachable predictor of 1-year HCC progression after cTACE.
• The maximal PLR value indicates the least lipiodol-distributed region in an HCC tumor. The maximal LLR value indicates the least lipiodol-deposited region in the tumor due to incomplete lipiodol delivery. PLR and LLR are concepts like signal-to-noise ratio to characterize the lipiodol retention pattern objectively to predict 1-year tumor progression immediately without any quantification software for 3D image analysis immediately after cTACE treatment. • COV of PLR can facilitate the early prediction of tumor progression/recurrence and indicate the section of embolized HCC, providing the operator's good targets for sequential cTACE or combined ablation. • The validation cohort in our study verified standard COVs of PLR and LLR. The validation process was more convincing and delicate than that of previous retrospective studies.
评估在接受常规经导管动脉化疗栓塞术(cTACE)治疗的肝细胞癌(HCC)患者中,基于 C 臂锥形束 CT(CBCT)的肝实质与碘化油比值(PLR)和病灶与碘化油比值(LLR)能否预测 1 年肿瘤反应。
本回顾性分析纳入了 2015 年至 2018 年间 80 例接受 cTACE 治疗并在动脉期 CBCT 和 cTACE 后行非增强 CBCT 的 HCC 靶病灶,共 221 个,符合 up-to-seven 标准。通过肝实质和肿瘤强化内碘化油沉积的平均密度划分,获得每个肿瘤切片的 PLR 和 LLR。使用约登指数分析每个肿瘤最大 PLR 和 LLR 的截止值(COV)。通过观察者间一致性和多变量分析评估 COV 的可靠性、相关参数之间的相关性以及 1 年进展情况。在验证队列中,通过卡方检验和 Cramer 的 V 系数(V)验证 COV 的有效性。
PLR 和 LLR 的标准 COV 分别为 0.149 和 1.4872。PLR 和 LLR 的 COV 观察者间一致性近乎完美(kappa>0.9)。多变量分析表明 PLR 的 COV 是独立的预测因素(比值比=1.23532×10,p=4.37×10)。PLR 的 COV 具有很强的一致性,与预测模型中的 1 年进展相关(V=0.829-0.776;p<0.0001),并且在验证队列中表现为有效的预测因子(V=0.766;p<0.0001)。
即刻栓塞后 CBCT 评估的 PLR COV(0.149)是 cTACE 后 1 年 HCC 进展的客观、有效和可接近的预测因子。
• PLR 的最大值表示 HCC 肿瘤中碘化油分布最少的区域。LLR 的最大值表示肿瘤中碘化油沉积最少的区域,因为碘化油输送不完全。PLR 和 LLR 是类似于信噪比的概念,可以客观地描述碘化油保留模式,从而无需任何 3D 图像分析的定量软件即可在 cTACE 治疗后即刻预测 1 年肿瘤进展。
• PLR 的 COV 有助于早期预测肿瘤进展/复发,并提示栓塞 HCC 的节段,为连续 cTACE 或联合消融提供了良好的目标。
• 本研究的验证队列验证了 PLR 和 LLR 的标准 COV。验证过程比以前的回顾性研究更具说服力和精细。